These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 21858810)

  • 41. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro and in vivo induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program.
    Cochlovius B; Stassar M; Christ O; Raddrizzani L; Hammer J; Mytilineos I; Zöller M
    J Immunol; 2000 Oct; 165(8):4731-41. PubMed ID: 11035118
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.
    Okada H; Tsugawa T; Sato H; Kuwashima N; Gambotto A; Okada K; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Chambers WH; Potter DM; Storkus WJ; Pollack IF
    Cancer Res; 2004 Aug; 64(16):5830-8. PubMed ID: 15313927
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide.
    Perambakam S; Hallmeyer S; Reddy S; Mahmud N; Bressler L; DeChristopher P; Mahmud D; Nunez R; Sosman JA; Peace DJ
    Cancer Immunol Immunother; 2006 Sep; 55(9):1033-42. PubMed ID: 16283303
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
    Xu M; Kallinteris NL; von Hofe E
    Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
    Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
    Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.
    Kumai T; Matsuda Y; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
    Br J Cancer; 2013 Oct; 109(8):2155-66. PubMed ID: 24045666
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin.
    Wobser M; Keikavoussi P; Kunzmann V; Weininger M; Andersen MH; Becker JC
    Cancer Immunol Immunother; 2006 Oct; 55(10):1294-8. PubMed ID: 16315030
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity.
    Laubreton D; Bay S; Sedlik C; Artaud C; Ganneau C; Dériaud E; Viel S; Puaux AL; Amigorena S; Gérard C; Lo-Man R; Leclerc C
    Cancer Immunol Immunother; 2016 Mar; 65(3):315-25. PubMed ID: 26847142
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preclinical development of HIvax: Human survivin highly immunogenic vaccines.
    Hoffmann PR; Panigada M; Soprana E; Terry F; Bandar IS; Napolitano A; Rose AH; Hoffmann FW; Ndhlovu LC; Belcaid M; Moise L; De Groot AS; Carbone M; Gaudino G; Matsui T; Siccardi A; Bertino P
    Hum Vaccin Immunother; 2015; 11(7):1585-95. PubMed ID: 26042612
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.
    Zeis M; Siegel S; Wagner A; Schmitz M; Marget M; Kühl-Burmeister R; Adamzik I; Kabelitz D; Dreger P; Schmitz N; Heiser A
    J Immunol; 2003 Jun; 170(11):5391-7. PubMed ID: 12759413
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.
    Fuessel S; Meye A; Schmitz M; Zastrow S; Linné C; Richter K; Löbel B; Hakenberg OW; Hoelig K; Rieber EP; Wirth MP
    Prostate; 2006 Jun; 66(8):811-21. PubMed ID: 16482569
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The study of anti-tumor activities of DC vaccine loaded with multi-epotipes of survivin].
    Guo M; Wang XY; Song WZ; Li XN; Liang X; Li Y; Huang ZL
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Nov; 27(11):1180-3. PubMed ID: 22078442
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Distinct patient responses to activation of T-cells by free HER-2, G89 (777-789) and protected LRMK-linked HER-2, {AE-39 [p776 (Ava-774-788)], AE-47 [(Ava-776-788)] and AE-37[p776 (774-788)]} peptides could lead to development of personalized cancer vaccines.
    Li Y; Matsueda S; Efferson CL; Tsuda N; Kawano K; Gao H; Peoples GE; Ioannides CG
    Anticancer Res; 2009 Jan; 29(1):41-58. PubMed ID: 19331132
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53.
    Kumai T; Ishibashi K; Oikawa K; Matsuda Y; Aoki N; Kimura S; Hayashi S; Kitada M; Harabuchi Y; Celis E; Kobayashi H
    Cancer Immunol Immunother; 2014 May; 63(5):469-78. PubMed ID: 24633296
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model.
    Siegel S; Wagner A; Schmitz N; Zeis M
    Br J Haematol; 2003 Sep; 122(6):911-4. PubMed ID: 12956760
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer.
    Tsuruma T; Iwayama Y; Ohmura T; Katsuramaki T; Hata F; Furuhata T; Yamaguchi K; Kimura Y; Torigoe T; Toyota N; Yagihashi A; Hirohashi Y; Asanuma H; Shimozawa K; Okazaki M; Mizushima Y; Nomura N; Sato N; Hirata K
    J Transl Med; 2008 May; 6():24. PubMed ID: 18471305
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic Vaccination against A Modified Minimal Survivin Epitope Induces Functional CD4 T Cells That Recognize Survivin-Expressing Cells.
    Nitschke NJ; Bjoern J; Met O; Svane IM; Andersen MH
    Scand J Immunol; 2016 Sep; 84(3):191-3. PubMed ID: 27354164
    [No Abstract]   [Full Text] [Related]  

  • 59. CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma.
    Ait-Tahar K; Liggins AP; Collins GP; Campbell A; Barnardo M; Cabes M; Lawrie CH; Moir D; Hatton C; Banham AH; Pulford K
    Haematologica; 2011 Jan; 96(1):78-86. PubMed ID: 20851862
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer--results from phase I clinical trials.
    Tanaka T; Kitamura H; Inoue R; Nishida S; Takahashi-Takaya A; Kawami S; Torigoe T; Hirohashi Y; Tsukamoto T; Sato N; Masumori N
    Clin Dev Immunol; 2013; 2013():262967. PubMed ID: 24363758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.